Epilepsy. Epilepsy and recurrent seizures
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group take one Empagliflozin pill per day with dosage of 25 mg, for 3 months. Intervention 2: Control group: Patients in this gruop take one placeb
Sponsors
Neuroscience Research Center of Imam Khomeini hospital
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Patients who have drug-resistant epilepsy and have tried two insufficient and different medical treatment Age between 18 to 45
Exclusion criteria
Exclusion criteria: Other neurological disorders Metabolic disorders Dyslipidemia Kidney diseases Active infection Patient refuse to continue the study Showing the unregistered side effects of drug BMI more than 30 and less than 18.5 Non- compliant patients Pregnancy Patients with ketogenic diet Patients with carbonic anhydrase inhibitor medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seizure frequnecies. Timepoint: Baseline, 30 days, and 90 days after starting the drug/placebo. Method of measurement: Daily calendar of the patients relating to their convulsions.;Seizure severity. Timepoint: Baseline, 30 days, and 90 days after starting the drug/placebo. Method of measurement: Evaluating the seizure diary. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood sugar, A1C, lipid profile, serum electrolytes ( K, Na, P, Ca ), VBG, urine analysis, CBC. Timepoint: Baseline, 30 days, and 90 days after starting the drug/placebo. Method of measurement: Laboratory kits. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSheida Mobader sani
Tehran University of Medical Sciences
Outcome results
None listed